Change of Director's Interest Notice x2
Released
Released
Announcement PDF
ASX Announcement
23 November 2023
APPENDIX 3Y
Melbourne, Australia, 23 November 2023: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the
“Company”), submits the Appendix 3Y of Dr Gregory Collier and Mr Matthew McNamara.
For enquiries, please contact
Ms Melanie Leydin
Company Secretary
Avecho Biotechnology Limited
+61 3 9002 5000
This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.
About Avecho
Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products
using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived
from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and
oral, dermal and transdermal absorption of drugs and nutrients.
Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the
human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.
See more here - avecho.com.au
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity: Avecho Biotechnology Limited
ABN
32 056 482 403
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Gregory Collier
Date of last notice
10 May 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Indirect
Nature of indirect interest
(including registered holder)
Barwon Biotechnology Pty Ltd
Note: Provide details of the circumstances giving rise to the relevant
interest.
Dr Collier is a director and shareholder of the
entity.
Date of change
22 November 2023
No. of securities held prior to change
Direct
5,990,465 unlisted options exercisable at $0.0169
each and expiring on 29 November 2024.
Indirect
Beacon Super Fund Pty Ltd <Beacon Super Fund
A/c>
4,000,000 Fully Paid Ordinary Shares.
Beacon Super Fund Pty Ltd <Beacon Super Fund
A/c>
3,000,000 Quoted Options exercisable at $0.012
each and expiring on 10 May 2026
Class
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
1.
2.
Fully Paid Ordinary Shares (AVE)
Quoted Options exercisable at $0.012 each
and expiring on 10 May 2026 (AVEOA)
Appendix 3Y
Change of Director’s Interest Notice
Number acquired
1.
2.
Number disposed
N/A
Value/Consideration
1.
2.
Note: If consideration is non-cash, provide details and estimated valuation
No. of securities held after change
5,833,333
8,749,999
$0.006 per Fully Paid Ordinary Share
Nil (free attaching Options)
Direct
5,990,465 unlisted options exercisable at $0.0169
each and expiring on 29 November 2024 (AVEAS)
Indirect
Beacon Super Fund Pty Ltd <Beacon Super Fund
A/c>
4,000,000 Fully Paid Ordinary Shares (AVE)
Beacon Super Fund Pty Ltd <Beacon Super Fund
A/c>
3,000,000 Quoted Options exercisable at $0.012
each and expiring on 10 May 2026 (AVEOA)
Barwon Biotechnology Pty Ltd
1. 5,833,333 Fully Paid Ordinary Shares (AVE)
2. 8,749,999 Quoted Options exercisable at
$0.012 each and expiring on 10 May 2026
(AVEOA)
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Issue of securities following shareholder approval
at the General Meeting on 9 November 2023 on
Resolution 4(b).
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Interest disposed
N/A
Value/Consideration
N/A
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed No
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade N/A
to proceed during this period?
If prior written clearance was provided, on what date was this N/A
provided?
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Avecho Biotechnology Limited
ABN
32 056 482 403
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Matthew Patrick McNamara
Date of last notice
31 May 2021
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Indirect
Nature of indirect interest
(including registered holder)
MLAKS PTY LIMITED <M & L MCNAMARA S/F
A/C>
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
Mr McNamara is director and shareholder of the
entity. He is also a beneficiary of the super fund.
22 November 2023
No. of securities held prior to change
Indirect
MLAKS PTY LTD <M & L MCNAMARA SUPER A/C>
3,993,644 Unlisted options exercisable at
$0.0169 each and expiring on 29 November 2024
(AVEAS)
Class
1.
2.
Fully Paid Ordinary Shares (AVE)
Quoted Options exercisable at $0.012 each
and expiring on 10 May 2026 (AVEOA)
Number acquired
1.
2.
1,666,666
2,499,999
Number disposed
Nil
Value/Consideration
1.
2.
Note: If consideration is non-cash, provide details and estimated valuation
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
$0.006 per Fully Paid Ordinary Share
Nil (free attaching Options)
Appendix 3Y
Change of Director’s Interest Notice
No. of securities held after change
Indirect
MLAKS PTY LIMITED <M & L McNAMARA SUPER
A/C>
3,993,644 Unlisted options exercisable at
$0.0169 each and expiring on 29 November
2024 (AVEAS)
1,666,666 Fully Paid Ordinary Shares (AVE)
2,499,999 quoted options exercisable at
$0.012 each and expiring on 10 May 2026
(AVEOA)
Nature of change
Issue of securities following shareholder approval
at the General Meeting on 9 November 2023 on
Resolution 4(a).
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – +Closed period
Were the interests in the securities or contracts detailed No
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade N/A
to proceed during this period?
If prior written clearance was provided, on what date was this N/A
provided?
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Share your feedback
Discover